Quarterly report pursuant to Section 13 or 15(d)

License Agreements (Details Textual)

v3.7.0.1
License Agreements (Details Textual) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Mar. 31, 2017
May 31, 2016
Sep. 30, 2015
May 31, 2015
Mar. 31, 2015
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Dec. 31, 2015
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Stock Issued During Period, Value, Issued for Services               $ 0    
Proceeds from Issuance of Common Stock               0 $ 570,000  
Revenue from Related Parties           $ 351,000 $ 1,249,000 1,044,000 1,526,000  
Neupharma [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Payment Of Upfront Fees         $ 1,000,000          
Revenue from Related Parties           197,000 221,000 397,000 481,000  
Neupharma [Member] | Additional Sales Milestone [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Maximum Potential Milestone Payments           40,000,000   40,000,000    
Neupharma [Member] | Clinical Development Milestone [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Maximum Potential Milestone Payments           40,000,000   40,000,000    
Neupharma [Member] | Regulatory Approvals To Commercialize The Products [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Maximum Potential Milestone Payments           22,500,000   22,500,000    
Dana-Farber [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Shares Issued, Price Per Share       $ 0.065            
Stock Issued During Period, Shares, Issued for Services     136,830 500,000            
Stock Issued During Period, Value, Issued for Services     $ 600,000 $ 32,500            
Payment Of Upfront Fees         $ 1,000,000          
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners       5.00%            
Proceeds from Issuance of Common Stock     $ 10,000,000              
Dana-Farber [Member] | Clinical Development, Regulatory and First Commercial Sale Milestone [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Revenue Recognition Milestone Method, Payments Due           21,500,000   21,500,000    
Maximum Potential Milestone Payments           21,500,000   21,500,000    
Dana-Farber [Member] | Additional Sales Milestone [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Revenue Recognition Milestone Method, Payments Due           60,000,000   60,000,000    
Maximum Potential Milestone Payments           60,000,000   60,000,000    
Teva Pharmaceutical Industries Ltd [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Payment Of Upfront Fees                   $ 500,000
Teva Pharmaceutical Industries Ltd [Member] | Clinical Development Milestone [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Maximum Potential Milestone Payments           206,500,000   206,500,000    
Teva Pharmaceutical Industries Ltd [Member] | Regulatory Approvals To Commercialize The Products [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Maximum Potential Milestone Payments           220,000,000   220,000,000    
Jubilant Biosys Ltd [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Nonrefundable Milestone Received   $ 1,000,000                
Payment Of Upfront Fees   $ 2,000,000                
Payment For Non refundable Milestone payments $ 400,000                  
Research and Development Cost, Shared Percentage   50.00%                
Revenue from Related Parties           144,000 1,000,000 608,000 1,000,000  
Jubilant Biosys Ltd [Member] | Clinical Development Milestone [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Revenue Recognition Milestone Method, Payments Due           87,200,000   87,200,000    
Maximum Potential Milestone Payments           88,500,000   88,500,000    
Jubilant Biosys Ltd [Member] | Regulatory Approvals To Commercialize The Products [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Maximum Potential Milestone Payments           59,500,000   59,500,000    
Jubilant Biosys Ltd [Member] | Completion Of Three Clinical Development Milestones For Two Licensed Products [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Revenue Recognition Milestone Method, Payments Due           25,500,000   25,500,000    
Jubilant Biosys Ltd [Member] | Five Regulatory Approvals And First Commercial Sales [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Revenue from Related Parties               61,700,000    
Jubilant Biosys Ltd [Member] | Three Sales Milestones Based On Aggregate Net Sales [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Revenue Recognition Milestone Method, Payments Due           89,000,000   89,000,000    
Jubilant Biosys Ltd [Member] | Sale Millstone [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Maximum Potential Milestone Payments           89,000,000   89,000,000    
Collaboration Agreement With TGTX [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Payment Of Upfront Licensing Fee               500,000    
Revenue from Related Parties           9,000 $ 3,000 38,000 $ 20,000  
Collaboration Agreement With TGTX [Member] | Clinical Development Milestone [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Revenue Recognition Milestone Method, Payments Due           7,000,000   7,000,000    
Collaboration Agreement With TGTX [Member] | Commercial Sales In Specified Territories [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Revenue Recognition Milestone Method, Payments Due           $ 14,500,000   $ 14,500,000